These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

302 related articles for article (PubMed ID: 21830835)

  • 1. A benefit-risk assessment of agomelatine in the treatment of major depression.
    Howland RH
    Drug Saf; 2011 Sep; 34(9):709-31. PubMed ID: 21830835
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Critical appraisal and update on the clinical utility of agomelatine, a melatonergic agonist, for the treatment of major depressive disease in adults.
    Howland RH
    Neuropsychiatr Dis Treat; 2009; 5():563-76. PubMed ID: 19966905
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Agomelatine treatment of major depressive disorder.
    Dolder CR; Nelson M; Snider M
    Ann Pharmacother; 2008 Dec; 42(12):1822-31. PubMed ID: 19033480
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treating each and every depressed patient.
    Kennedy SH
    J Psychopharmacol; 2008 Sep; 22(7 Suppl):19-23. PubMed ID: 18753279
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Agomelatine: a preliminary review of a new antidepressant.
    Zupancic M; Guilleminault C
    CNS Drugs; 2006; 20(12):981-92. PubMed ID: 17140278
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Agomelatine prevents relapse in patients with major depressive disorder without evidence of a discontinuation syndrome: a 24-week randomized, double-blind, placebo-controlled trial.
    Goodwin GM; Emsley R; Rembry S; Rouillon F;
    J Clin Psychiatry; 2009 Aug; 70(8):1128-37. PubMed ID: 19689920
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The efficacy of agomelatine in previously-treated depressed patients.
    Kasper S; Hajak G
    Eur Neuropsychopharmacol; 2013 Aug; 23(8):814-21. PubMed ID: 23820051
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of agomelatine, a MT1/MT2 receptor agonist with 5-HT2C antagonistic properties, in major depressive disorder.
    Olié JP; Kasper S
    Int J Neuropsychopharmacol; 2007 Oct; 10(5):661-73. PubMed ID: 17477888
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Agomelatine efficacy and acceptability revisited: systematic review and meta-analysis of published and unpublished randomised trials.
    Koesters M; Guaiana G; Cipriani A; Becker T; Barbui C
    Br J Psychiatry; 2013 Sep; 203(3):179-87. PubMed ID: 23999482
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Beyond the monoaminergic hypothesis: agomelatine, a new antidepressant with an innovative mechanism of action.
    Kasper S; Hamon M
    World J Biol Psychiatry; 2009; 10(2):117-26. PubMed ID: 19255935
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Agomelatine: efficacy at each phase of antidepressant treatment.
    Kennedy SH
    CNS Drugs; 2009; 23 Suppl 2():41-7. PubMed ID: 19708725
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of the novel antidepressant agomelatine for anxiety symptoms in major depression.
    Stein DJ; Picarel-Blanchot F; Kennedy SH
    Hum Psychopharmacol; 2013 Mar; 28(2):151-9. PubMed ID: 23532747
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antidepressant efficacy of agomelatine: meta-analysis of published and unpublished studies.
    Taylor D; Sparshatt A; Varma S; Olofinjana O
    BMJ; 2014 Mar; 348():g1888. PubMed ID: 24647162
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Agomelatine: new drug. Adverse effects and no proven efficacy.
    Prescrire Int; 2009 Dec; 18(104):241-5. PubMed ID: 20020562
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Melatonin and agomelatine for preventing seasonal affective disorder.
    Nussbaumer-Streit B; Greenblatt A; Kaminski-Hartenthaler A; Van Noord MG; Forneris CA; Morgan LC; Gaynes BN; Wipplinger J; Lux LJ; Winkler D; Gartlehner G
    Cochrane Database Syst Rev; 2019 Jun; 6(6):CD011271. PubMed ID: 31206585
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Agomelatine in the treatment of major depressive disorder: potential for clinical effectiveness.
    Kennedy SH; Rizvi SJ
    CNS Drugs; 2010 Jun; 24(6):479-99. PubMed ID: 20192279
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Agomelatine in depression.
    Smeraldi E; Delmonte D
    Expert Opin Drug Saf; 2013 Nov; 12(6):873-80. PubMed ID: 24033095
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Agomelatine for the treatment of major depressive disorder.
    Carney RM; Shelton RC
    Expert Opin Pharmacother; 2011 Oct; 12(15):2411-9. PubMed ID: 21916789
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The antidepressant agomelatine improves the quality of life of depressed patients: implications for remission.
    Llorca PM
    J Psychopharmacol; 2010 Aug; 24(2 Suppl):21-6. PubMed ID: 20663805
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Agomelatine in the treatment of major depressive disorder: an 8-week, multicenter, randomized, placebo-controlled trial.
    Stahl SM; Fava M; Trivedi MH; Caputo A; Shah A; Post A
    J Clin Psychiatry; 2010 May; 71(5):616-26. PubMed ID: 20361916
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.